Cell Free DNA in Mature B-cell Lymphoma

Prospective, Observational Study on Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Lymphoma Management

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04088422

Enrollment

320

Registered

2019-09-12

Start date

2022-09-28

Completion date

2026-12-31

Last updated

2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mature B-Cell Lymphoma

Brief summary

The purpose of this study is to assess whether plasma cell free DNA is an accurate tool that can early and dynamically inform on treatment outcome and an accessible source of tumor DNA to track tumor clonal evolution.

Interventions

PROCEDUREperipheral blood collection

peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria * 18 years or older

Exclusion criteria

* Chemotherapy before * Other tumors

Design outcomes

Primary

Measure	Time frame
progression free survival	2-year

Secondary

Measure	Time frame
overall survival	2-year
Complete Response rate	6 weeks after treatment

Countries

China

Contacts

Primary ContactWeili Zhao, MD，PhD

zhao.weili@yahoo.com64370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026